2.5 milliondeaths per year
are prevented by vaccines
5lives every minute
are saved by vaccines worldwide
2.5 milliondeaths per year
are prevented by vaccines
5lives every minute
are saved by vaccines worldwide
about
mAXVAX
Technology
& production
Maxvax has pioneered three technological platforms: recombinant protein, adjuvants, and mRNA, aimed at treating infectious diseases, cancer, and allergies.
Learn moreTechnology
Platform
+
Utilizing our technology platforms, we have developed a diverse pipeline of prophylactic and therapeutic vaccines to combat global health burdens.
Learn morePipeline
Introduction
+
We have constructed over 200,000 sq ft of state-of-the-art R&D and manufacturing facilities to support our pipeline, enabling us to handle product development all the way to industrial scale manufacturing, all in-house.
Learn more...Production
Capability
+
news
center
On April 12, 2024, Chengdu Maxvax Biotechnology LLC. (hereinafter referred to as “Maxvax”) announced the IND application for its recombinant protein respiratory syncytial virus (RSV) vaccine (CHO cell) has been officially accepted by the Center for Drug Evaluation (CDE) of China’s State Drug Administration (Acceptance No.: CXSL2400228).
more >
Recently, Chengdu Maxvax Biotechnology LLC. (hereinafter referred to as "Maxvax") announced the completion of its Series C financing round, raising nearly 300 million CNY.
more >
Maxvax has received funding from the Bill & Melinda Gates Foundation to support the development of a low-cost HPV therapeutic vaccine candidate, aligning with global efforts to address the challenges posed by HPV infection that can lead to cervical cancer.
more >